Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Proactive Investors One2One Investor Forum - London

Netscientific PLC | Amryt Pharmaceuticals | Evgen Pharma | Tissue Regenix Group PLC | Summit Therapeutics PLC

The presentations will start at 6:00pm and finish at approx 8:00pm. After the presentations are complete the directors will also be available to take questions during a free canapé and wine reception. Details on the presenting companies can be found below.

 

This event is suitable for the following:

Sophisticated & private investors, private client brokers, fund managers, financial institutions, hedge funds, buy & sell side analysts and journalists.

 

The event is not suitable for people pursuing commercial opportunities.

Amryt Pharmaceuticals

RSS Portfolio

Amryt_Pharma_59677939c44cb.png


Amryt Pharma is a commercial stage pharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases.

EPIC: AMYT
Market: AIM
52-week High/Low: 29.50p / 16.70p
Market Cap: 48.64M


View full company profile

Evgen Pharma

RSS Portfolio

ev1.png


Evgen Pharma plc, a clinical stage drug development company focused on the treatment of cancer and neurological conditions.

EPIC: EVG
Market: AIM
52-week High/Low: 25.00p / 12.15p
Market Cap: 11.73M


View full company profile

Netscientific PLC

RSS Portfolio

netscientific-logo.png


NetScientific's mission is to build a transatlantic biomedical and healthcare group funding and developing technologies that offer transformative benefits to people's lives and society.

NetScientific funds, develops and manages early/mid-stage healthcare technology companies sourced from strategic partnerships and relationships in USA and Europe with a primary focus on Digital health, Diagnostics and Therapeutics. These represent highly attractive growth markets where breakthrough technology solutions are in high demand.

NetScientific is an active investor providing extensive management support. This can involve the senior management team initially taking leadership roles in companies and building dedicated management teams as the companies develop and grow.

EPIC: NSCI
Market: AIM
52-week High/Low: 77.00p / 36.00p
Market Cap: 38.10M


View full company profile

Summit Therapeutics PLC

RSS Portfolio

summit_corp_logo.png


We are seeking to treat all boys and young men afflicted with the fatal disease Duchenne muscular dystrophy with our pioneering utrophin modulation technology.

We are also advancing a highly selective novel antibiotic for C. difficile infection.

EPIC: SUMM
Market: AIM
52-week High/Low: 269.70p / 111.00p
Market Cap: 155.61M


View full company profile

Tissue Regenix Group PLC

RSS Portfolio

tissue_regenix_sponsor_logo.png


Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company’s patented decellularisation (‘dCELL®) technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient’s body which can then be used to repair diseased or worn-out body parts. The potential applications for this process are diverse and address many critical clinical needs such as treating vascular disease, heart valve replacement and knee repair.

Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.

Tissue Regenix is based in York and has an operation in San Antonio, USA

EPIC: TRX
Market: AIM
52-week High/Low: 16.75p / 5.50p
Market Cap: 120.80M


View full company profile

© Proactive Investors 2018

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use